{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,6,13]],"date-time":"2025-06-13T09:43:30Z","timestamp":1749807810730,"version":"3.37.3"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"6","license":[{"start":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T00:00:00Z","timestamp":1549929600000},"content-version":"tdm","delay-in-days":0,"URL":"http:\/\/www.springer.com\/tdm"}],"funder":[{"DOI":"10.13039\/501100012166","name":"National key research and development program of China","doi-asserted-by":"crossref","award":["No. 2017YFC0909002"],"award-info":[{"award-number":["No. 2017YFC0909002"]}],"id":[{"id":"10.13039\/501100012166","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2019,6]]},"DOI":"10.1007\/s10067-018-04424-x","type":"journal-article","created":{"date-parts":[[2019,2,12]],"date-time":"2019-02-12T09:26:07Z","timestamp":1549963567000},"page":"1587-1594","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":4,"title":["Effective serum level of etanercept biosimilar and effect of antidrug antibodies on drug levels and clinical efficacy in Chinese patients with ankylosing spondylitis"],"prefix":"10.1007","volume":"38","author":[{"given":"Yidian","family":"Dong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ping","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tingshuang","family":"Xu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liqi","family":"Bi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2019,2,12]]},"reference":[{"key":"4424_CR1","doi-asserted-by":"publisher","first-page":"346","DOI":"10.1136\/ard.2007.078139","volume":"67","author":"JC Davis Jr","year":"2008","unstructured":"Davis JC Jr, van der Heijde DM, Braun J et al (2008) Efficacy and safety of up to 192 weeks of etanercept therapy in patients with ankylosing spondylitis. Ann Rheum Dis 67:346\u2013352","journal-title":"Ann Rheum Dis"},{"key":"4424_CR2","first-page":"61","volume":"35","author":"S Arends","year":"2017","unstructured":"Arends S, Brouwer E, Efde M et al (2017) Long-term drug survival and clinical effectiveness of etanercept treatment in patients with ankylosing spondylitis in daily clinical practice. Clin Exp Rheumatol 35:61\u201368","journal-title":"Clin Exp Rheumatol"},{"key":"4424_CR3","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1080\/03009742.2017.1330419","volume":"47","author":"J Ruwaard","year":"2018","unstructured":"Ruwaard J, l\u2019Ami MJ, Marsman AF et al (2018) Comparison of drug survival and clinical outcome in patients with ankylosing spondylitis treated with etanercept or adalimumab. Scand J Rheumatol 47:122\u2013126","journal-title":"Scand J Rheumatol"},{"key":"4424_CR4","doi-asserted-by":"publisher","first-page":"430","DOI":"10.1038\/nrrheum.2012.84","volume":"8","author":"MA Scheinberg","year":"2012","unstructured":"Scheinberg MA, Kay J (2012) The advent of biosimilar therapies in rheumatology\u2014\u201cO brave new world\u201d. Nat Rev Rheumatol 8:430\u2013436","journal-title":"Nat Rev Rheumatol"},{"key":"4424_CR5","doi-asserted-by":"publisher","first-page":"322","DOI":"10.1136\/annrheumdis-2012-202715","volume":"72","author":"T D\u00f6rner","year":"2013","unstructured":"D\u00f6rner T, Strand V, Casta\u00f1eda-Hern\u00e1ndez G, Ferraccioli G, Isaacs JD, Kvien TK, Martin-Mola E, Mittendorf T, Smolen JS, Burmester GR (2013) The role of biosimilars in the treatment of rheumatic diseases. Ann Rheum Dis 72:322\u2013328","journal-title":"Ann Rheum Dis"},{"key":"4424_CR6","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1007\/s10067-016-3424-5","volume":"36","author":"Y An","year":"2017","unstructured":"An Y, Liu T, He D, Wu L, Li J, Liu Y, Bi L, Zhou B, Lin C, He L, Liu X, Li X, Yang N, Zhang Z, Song H, Wei W, Liu J, Bi Y, Li Z (2017) The usage of biological DMARDs and clinical remission of rheumatoid arthritis in China: a real-world large scale study. Clin Rheumatol 36:35\u201343","journal-title":"Clin Rheumatol"},{"key":"4424_CR7","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1007\/s10067-013-2372-6","volume":"33","author":"R Stefano De","year":"2014","unstructured":"De Stefano R, Frati E, De Quattro D, Menza L, Manganelli S (2014) Low doses of etanercept can be effective to maintain remission in ankylosing spondylitis patients. Clin Rheumatol 33:707\u2013711","journal-title":"Clin Rheumatol"},{"key":"4424_CR8","doi-asserted-by":"publisher","first-page":"2271","DOI":"10.1007\/s00296-011-1920-0","volume":"32","author":"J Moghimi","year":"2012","unstructured":"Moghimi J, Sheikhvatan M, Semnani V (2012) The use of low-dose etanercept as an alternative therapy for treatment of ankylosing spondylitis a case series. Rheumatol Int 32:2271\u20132274","journal-title":"Rheumatol Int"},{"key":"4424_CR9","doi-asserted-by":"publisher","first-page":"1825","DOI":"10.1136\/annrheumdis-2014-205213","volume":"74","author":"EL Kneepkens","year":"2015","unstructured":"Kneepkens EL, Krieckaert CL, van der Kleij D et al (2015) Lower etanercept levels are associated with high disease activity in ankylosing spondylitis patients at 24 weeks of follow-up. Ann Rheum Dis 74:1825\u20131829","journal-title":"Ann Rheum Dis"},{"key":"4424_CR10","doi-asserted-by":"publisher","first-page":"88","DOI":"10.1136\/annrheumdis-2011-200184","volume":"71","author":"A Jamnitski","year":"2012","unstructured":"Jamnitski A, Krieckaert CL, Nurmohamed MT, Hart MH, Dijkmans BA, Aarden L, Voskuyl AE, Wolbink GJ (2012) Patients non-responding to etanercept obtain lower etanercept concentrations compared with responding patients. Ann Rheum Dis 71:88\u201391","journal-title":"Ann Rheum Dis"},{"key":"4424_CR11","doi-asserted-by":"publisher","first-page":"1429","DOI":"10.1007\/s10067-013-2336-x","volume":"32","author":"CC Mok","year":"2013","unstructured":"Mok CC, van der Kleij D, Wolbink GJ (2013) Drug levels, anti-drug antibodies, and clinical efficacy of the anti-TNF\u03b1 biologics in rheumatic diseases. Clin Rheumatol 32:1429\u20131435","journal-title":"Clin Rheumatol"},{"key":"4424_CR12","doi-asserted-by":"publisher","first-page":"1787","DOI":"10.1136\/ard.2009.109702","volume":"68","author":"MK Vries de","year":"2009","unstructured":"de Vries MK, Brouwer E, van der Horst-Bruinsma IE et al (2009) Decreased clinical response to adalimumab in ankylosing spondylitis is associated with antibody formation. Ann Rheum Dis 68:1787\u20131788","journal-title":"Ann Rheum Dis"},{"key":"4424_CR13","doi-asserted-by":"publisher","first-page":"1252","DOI":"10.1136\/ard.2007.072397","volume":"66","author":"MK Vries de","year":"2007","unstructured":"de Vries MK, Wolbink GJ, Stapel SO, de Vrieze H, van Denderen JC, Dijkmans BAC, Aarden LA, van der Horst-Bruinsma IE (2007) Decreased clinical response to infliximab in ankylosing spondylitis is correlated with anti- infliximab formation. Ann Rheum Dis 66:1252\u20131254","journal-title":"Ann Rheum Dis"},{"key":"4424_CR14","first-page":"661","volume":"28","author":"S Arends","year":"2010","unstructured":"Arends S, Lebbink HR, Spoorenberg A et al (2010) The formation of autoantibodies and antibodies to TNF-\u03b1 blocking agents in relation to clinical response in patients with ankylosing spondylitis. Clin Exp Rheumatol 28:661\u2013668","journal-title":"Clin Exp Rheumatol"},{"key":"4424_CR15","doi-asserted-by":"publisher","first-page":"82","DOI":"10.1007\/s12016-009-8140-3","volume":"38","author":"N Emi Aikawa","year":"2010","unstructured":"Emi Aikawa N, de Carvalho JF, Artur Almeida Silva C, Bonf\u00e1 E (2010) Immunogenicity of anti-TNF-\u03b1 agents in autoimmune diseases. Clin Rev Allergy Immunol 38:82\u201389","journal-title":"Clin Rev Allergy Immunol"},{"key":"4424_CR16","doi-asserted-by":"publisher","first-page":"531","DOI":"10.1136\/ard.2008.089979","volume":"68","author":"MK Vries de","year":"2009","unstructured":"de Vries MK, van der Horst-Bruinsma IE, Nurmohamed MT et al (2009) Immunogenicity does not influence treatment with etanercept in patients with ankylosing spondylitis. Ann Rheum Dis 68:531\u2013535","journal-title":"Ann Rheum Dis"},{"key":"4424_CR17","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1002\/art.1780270401","volume":"27","author":"S Linden van der","year":"1984","unstructured":"van der Linden S, Valkenburg HA, Cats A (1984) Evaluation of diagnostic criteria for ankylosing spondylitis. A proposal for modification of the New York criteria. Arthritis Rheum 27:361\u2013368","journal-title":"Arthritis Rheum"},{"key":"4424_CR18","first-page":"2286","volume":"21","author":"S Garrett","year":"1994","unstructured":"Garrett S, Jenkinson T, Kennedy LG et al (1994) A new approach to defining disease status in ankylosing spondylitis the Bath Ankylosing Spondylitis Disease Activity Index. J Rheumatol 21:2286\u20132291","journal-title":"J Rheumatol"},{"key":"4424_CR19","doi-asserted-by":"publisher","first-page":"817","DOI":"10.1136\/ard.62.9.817","volume":"62","author":"J Braun","year":"2003","unstructured":"Braun J, Pham T, Sieper J, Davis J, van der Linden S, Dougados M, van der Heijde D, ASAS Working Group (2003) International ASAS consensus statement for the use of anti-tumour necrosis factor agents in patients with ankylosing spondylitis. Ann Rheum Dis 62:817\u2013824","journal-title":"Ann Rheum Dis"},{"key":"4424_CR20","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1136\/ard.2008.097774","volume":"68","author":"J Sieper","year":"2009","unstructured":"Sieper J, Rudwaleit M, Baraliakos X et al (2009) The Assessment of SpondyloArthritis international Society (ASAS) handbook: a guide to assess spondyloarthritis. Ann Rheum Dis 68:1\u201344","journal-title":"Ann Rheum Dis"},{"key":"4424_CR21","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1136\/ard.2010.138594","volume":"70","author":"P Machado","year":"2011","unstructured":"Machado P, Landew\u00e9 R, Lie E et al (2011) Ankylosing Spondylitis Disease Activity Score (ASDAS): defining cut-off values for disease activity states and improvement scores. Ann Rheum Dis 70:47\u201353","journal-title":"Ann Rheum Dis"},{"key":"4424_CR22","doi-asserted-by":"publisher","first-page":"489","DOI":"10.1136\/ard.2007.074724","volume":"67","author":"D Heijde van der","year":"2008","unstructured":"van der Heijde D, Landew\u00e9 R, Feldtkeller E (2008) Proposal of a linear definition of the Bath ankylosing spondylitis metrology index (BASMI) and comparison with the 2-step and 10-step definitions. Ann Rheum Dis 67:489\u2013493","journal-title":"Ann Rheum Dis"},{"key":"4424_CR23","doi-asserted-by":"publisher","first-page":"578","DOI":"10.1124\/jpet.104.079277","volume":"313","author":"JR Rojas","year":"2005","unstructured":"Rojas JR, Taylor RP, Cunningham MR, Rutkoski TJ, Vennarini J, Jang H, Graham MA, Geboes K, Rousselle SD, Wagner CL (2005) Formation, distribution,and elimination of infliximab and anti-infliximab immune complexes in cynomolgus monkeys. J Pharmacol Exp Ther 313:578\u2013585","journal-title":"J Pharmacol Exp Ther"},{"key":"4424_CR24","doi-asserted-by":"publisher","first-page":"1018","DOI":"10.1111\/1346-8138.13301","volume":"43","author":"R Kui","year":"2016","unstructured":"Kui R, G\u00e1l B, Ga\u00e1l M, Kiss M, Kem\u00e9ny L, Gyulai R (2016) Presence of antidrug antibodies correlates inversely with the plasma tumor necrosis factor (TNF)-\u03b1 level and the efficacy of TNF-inhibitor therapy in psoriasis. J Dermatol 43:1018\u20131023","journal-title":"J Dermatol"},{"key":"4424_CR25","doi-asserted-by":"publisher","DOI":"10.1155\/2014\/675108","volume":"2014","author":"M Schulz","year":"2014","unstructured":"Schulz M, Dotzlaw H, Neeck G (2014) Ankylosing spondylitis and rheumatoid arthritis serum levels of TNF-\u03b1 and its soluble receptors during the course of therapy with etanercept and infliximab. Biomed Res Int 2014:675108","journal-title":"Biomed Res Int"},{"key":"4424_CR26","doi-asserted-by":"publisher","first-page":"561","DOI":"10.1136\/ard.62.6.561","volume":"62","author":"J Zou","year":"2003","unstructured":"Zou J, Rudwaleit M, Brandt J, Thiel A, Braun J, Sieper J (2003) Up regulation of the production of tumour necrosis factor alpha and interferon gamma by T cells in ankylosing spondylitis during treatment with etanercept. Ann Rheum Dis 62:561\u2013564","journal-title":"Ann Rheum Dis"},{"key":"4424_CR27","doi-asserted-by":"publisher","first-page":"911","DOI":"10.1517\/14740338.2012.727796","volume":"11","author":"A Batycka-Baran","year":"2012","unstructured":"Batycka-Baran A, Flaig M, Molin S, Ruzicka T, Prinz JC (2012) Etanercept-induced injection site reactions: potential pathomechanisms and clinical assessment. Expert Opin Drug Saf 11:911\u2013921","journal-title":"Expert Opin Drug Saf"},{"key":"4424_CR28","doi-asserted-by":"publisher","first-page":"1515","DOI":"10.1136\/annrheumdis-2016-210931","volume":"76","author":"E Lie","year":"2017","unstructured":"Lie E, Lindstr\u00f6m U, Zverkova-Sandstr\u00f6m T, Olsen IC, Forsblad-d\u2019Elia H, Askling J, Kapetanovic MC, Kristensen LE, Jacobsson LTH (2017) Tumour necrosis factor inhibitor treatment and occurrence of anterior uveitis in ankylosing spondylitis: results from the Swedish biologics register. Ann Rheum Dis 76:1515\u20131521","journal-title":"Ann Rheum Dis"},{"key":"4424_CR29","first-page":"20","volume":"33","author":"B Wu","year":"2015","unstructured":"Wu B, Song Y, Leng L, Bucala R, Lu LJ (2015) Treatment of moderate rheumatoid arthritis with different strategies in a health resource-limited setting: a cost-effectiveness analysis in the era of biosimilars. Clin Exp Rheumatol 33:20\u201326","journal-title":"Clin Exp Rheumatol"},{"key":"4424_CR30","doi-asserted-by":"publisher","first-page":"691","DOI":"10.1016\/j.autrev.2012.08.013","volume":"12","author":"I Olivieri","year":"2013","unstructured":"Olivieri I, D\u2019Angelo S, Padula A, Leccese P, Nigro A, Palazzi C (2013) Can we reduce the dosage of biologics in spondyloarthritis? Autoimmun Rev 12:691\u2013693","journal-title":"Autoimmun Rev"},{"key":"4424_CR31","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1177\/0394632016656013","volume":"29","author":"J Li","year":"2016","unstructured":"Li J, Wang X, Han Z, Zhang Y, Wang Y, Zhang Y (2016) Dose reduction of recombinant human tumor necrosis factor inhibitors (etanercept) can be effective in ankylosing spondylitis patients with synovitis of the hip in a Chinese population. Int J Immunopathol Pharmacol 29:510\u2013515","journal-title":"Int J Immunopathol Pharmacol"},{"key":"4424_CR32","first-page":"592","volume":"34","author":"JW Park","year":"2016","unstructured":"Park JW, Yoon YI, Lee JH et al (2016) Low dose etanercept treatment for maintenance of clinical remission in ankylosing spondylitis. Clin Exp Rheumatol 34:592\u2013599","journal-title":"Clin Exp Rheumatol"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/link.springer.com\/article\/10.1007\/s10067-018-04424-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-04424-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-018-04424-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,13]],"date-time":"2023-09-13T15:36:12Z","timestamp":1694619372000},"score":1,"resource":{"primary":{"URL":"http:\/\/link.springer.com\/10.1007\/s10067-018-04424-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,2,12]]},"references-count":32,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2019,6]]}},"alternative-id":["4424"],"URL":"https:\/\/doi.org\/10.1007\/s10067-018-04424-x","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"type":"print","value":"0770-3198"},{"type":"electronic","value":"1434-9949"}],"subject":[],"published":{"date-parts":[[2019,2,12]]},"assertion":[{"value":"20 September 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"3 December 2018","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"28 December 2018","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"12 February 2019","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Disclosures"}},{"value":"This study was conducted in accordance with the ethical standards of the Helsinki Declaration and approved by the Ethical Committee of the China-Japan Union Hospital of Jilin University (approval number, 2015-wjw008). Each patient was selected following a rigorous process and provided written informed consent.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical statement"}}]}}